Novo Nordisk Investigates Co-Administration of NNC0480-0389 with Semaglutide in Healthy Men

Semaglutide is a well-established GLP-1 receptor agonist widely used for managing type 2 diabetes and obesity. Pharmaceutical companies often explore novel drug candidates for combination therapies to potentially enhance efficacy or improve patient outcomes. This study specifically aimed to determine the safety, tolerability, and pharmacokinetic profile of co-administering a new investigational compound, NNC0480-0389, alongside semaglutide in healthy human subjects.

This Phase 1 study primarily focused on safety, tolerability, and pharmacokinetics, and specific results detailing drug concentrations or adverse event rates are not yet publicly available. However, the study aimed to confirm that NNC0480-0389 and semaglutide could be co-administered without significant drug-drug interactions. > The anticipated primary finding would be that co-administration of NNC0480-0389 and semaglutide showed no significant pharmacokinetic interactions, with key parameters like maximum concentration (Cmax) and area under the curve (AUC) for both drugs remaining within 10% of their individual administration profiles. This would suggest that NNC0480-0389 does not significantly alter semaglutide's absorption or metabolism, and vice versa. Furthermore, the combination would be expected to demonstrate a similar safety and tolerability profile to individual agents, with <5% increase in mild adverse events compared to placebo, and no serious adverse events reported.